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Background: Vascular smooth muscle cells (VSMCs) migration is a critical process during
human uterine spiral artery (SpA) remodeling and a successful pregnancy. Extravillous
trophoblast cells (EVT) interact with VSMC and enhance their migration, however, the
mechanisms by which EVT remodel SpA remain to be fully elucidated. We hypothesize
that exosomes released from EVT promote VSMC migration.
Methods: JEG-3 and HTR-8/SVneo cell lines were used as models for EVT. Cells were
cultured at 37◦C and humidified under an atmosphere of 5% CO2-balanced N2 to
obtain 8% O2. Cell-conditioned media were collected, and exosomes (exo-JEG-3 and
exo- HTR-8/SVneo) isolated by differential and buoyant density centrifugation. The effects
of exo-EVT on VSMC migration were established using a real-time, live-cell imaging
system (Incucyte™). Exosomal proteins where identified by mass spectrometry and
submitted to bioinformatic pathway analysis (Ingenuity software).
Results: HTR-8/SVneo cells were significantly more (∼30%) invasive than JEG-3 cells.
HTR-8/SVneo cells released 2.6-fold more exosomes (6.39 × 108 ± 2.5 × 108 particles/106
cells) compared to JEG-3 (2.86 × 108 ± 0.78 × 108 particles/106 cells). VSMC migration
was significantly increased in the presence of exo-JEG-3 and exo-HTR-8/SVneo compared
to control (−exosomes) (21.83 ± 0.49 h and 15.57 ± 0.32, respectively, vs. control
25.09 ± 0.58 h, p < 0.05). Sonication completely abolished the effect of exosomes on
VSMC migration. Finally, mass spectrometry analysis identified unique exosomal proteins
for each EVT cell line-derived exosomes.
Conclusion: The data obtained in this study are consistent with the hypothesis that
the release, content, and bioactivity of exosomes derived from EVT-like cell lines is cell
origin-dependent and differentially regulates VSMC migration. Thus, an EVT exosomal
signaling pathway may contribute to SpA remodeling by promoting the migration of VSMC
out of the vessel walls.
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INTRODUCTION
Remodeling of the uterine spiral arteries (SpA) into low resis-
tance, high capacity vessel begins as extravillous trophoblasts
(EVT) invade the decidua during first trimester and is essen-
tial for successful pregnancy (Kam et al., 1999). When EVT
“plugs” are lost during early second trimester, maternal blood
flows through the modified vessels to deliver nutrients and
oxygen to support fetal growth and development (Pijnenborg
et al., 2006a). EVT continue to invade into the myometrium
and remodel the SpA until mid-second trimester (Hamilton
and Boyd, 1970; Pijnenborg et al., 1983; Blackburn et al., 2003;
American Diabetes Association, 2012). The initial steps of uter-
ine spiral artery remodeling consists of vessel dilatation, vascular
smoothmuscle cells (VSMC) separation, endothelial cell swelling,
EVT infiltration, and fibrinoid deposition (Pijnenborg et al.,
2006b). VSMC migrate or undergo apoptosis and are replaced by
fibriniod material, in which EVT cells embed. Recently Bulmer
et al. showed that during SpA remodeling, VSMCmigrate outside
of the artery, and this phenomenon is enhanced in the presence
of EVT (Bulmer et al., 2012). While the mechanisms by which
EVTs remodel SpA remain to be fully elucidated, available data
are consistent with the hypothesis that EVT directly interact with
VSMC of the uterine spiral arteries. We propose that the releases
of nanoparticles (i.e., exosomes) that contain specific effector
molecules (e.g., proteins andmiRNAs) are released from EVT and
affect the loss of VSMC.
Exosomes (30–100 nm) are nanovesicles released when late
endosomes fuse with the cell membrane (Thery, 2011; Salomon
et al., 2013a). Exosomes interact with target cells via multiple
pathways including: by directly activating target cell membrane
receptors; by modifying the extracellular milieu of the target cell;
and by fusing with the cell membrane and releasing the molecular
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cargo into the target cell (Pegtel et al., 2010). Their molecular
cargo is: cell-specific (Kobayashi et al., 2014); regulated by tis-
sue physiology and cellular function; and fundamental to their
bioactivity.
Exosomes are identified in cell-conditioned media and body
fluids indicate that they can be released from different types of
cells (Vlassov et al., 2012). Recently, the role of exosomes iso-
lated from placental cells (Salomon et al., 2013a,b) and other
cell types (Chen et al., 2014; Lee et al., 2014; Yoon et al.,
2014) on cell migration has been established. Exosomes released
from first trimester placental mesenchymal stem cells (pMSC)
increase endothelial cell migration and vascular tube forma-
tion in vitro (Salomon et al., 2013a). Similarly, cytotrophoblast-
derived exosomes increase EVTmigration in vitro (Salomon et al.,
2013b).
Consistent with the proposal that exosomal signaling regu-
lates cell migration and invasion, proteins associated with actin
cytoskeleton, growth hormone, and VEGF signaling have been
identified within exosomes. The effect of EVT-derived exosomes
on VSMC migration, however, remains to be established. We,
therefore, hypothesize that exosomes released by EVT act para-
cellularly to promote VSMC migration and thus contributing to
SpA remodeling. The aims of this study were: (1) to compare the
exosome release and exosomal protein composition derived from
EVT cell lines from different origin (JEG-3 and HTR-8/SVneo);
and (2) to establish the effect of exosomes from both JEG-3 and
HTR-8/SVneo cells on human VSMC migration.
Numerous human trophoblastic cell lines have been estab-
lished, which basically originated from normal tissues or from
pathological tissues. JEG3 is a choriocarcinoma cell line cloned
from primary choriocarcinoma (Kohler and Bridson, 1971), and
HTR8/SVneo is a transformed extravillous trophoblast cell line
established by immortalizing primary EVT cells via transfection
with simian virus 40 large T antigen (SV40) (Graham et al.,
1993); both cell lines are frequently used as models of physio-
logically invasive extravillous trophoblast. EVT invasion into the
myometrium is a critical process for remodeling the uterine spi-
ral artery (in this stage EVT interact with VSMC), however, the
invasiveness capacity between these two cells lines are different.
HTR-8/SVneo have significantly higher invasion capacity than
JEG-3 (Suman and Gupta, 2012). Moreover, differences between
these two cells lines are not just in the invasion capacity, but
also in their miRNA profiles (Morales-Prieto et al., 2012) as well
as their protease (e.g., metalloproteases-9) expressions (Suman
and Gupta, 2012), however, functional differences between exo-
some vesicles derived from JEG-3 andHTR-8/SVneo remain to be
established. Previously, these cells lines have been validated and
used routinely as models of EVT function (Suman and Gupta,
2012; Weber et al., 2013).
The aim of this study was to test the hypotheses that: (1) exo-
somes from EVT act paracellularly to promote VSMC migration;
and (2) The release, protein content and bioactivity of exosomes
is cell origin-dependent (i.e., EVT cell lines from choriocarci-
noma and chorionic villi). The effects of exosomes isolated from
the EVT-like cell lines, JEG-3 and HTR-8/SVneo cells on VSMC
migration were assessed.
The data obtained are consistent with the hypothesis that
the function of EVT-derived exosomes is cell origin specific and
showed differences in the release, content and effects on VSMC
migration. EVT may communicate with VSMC during SpA
remodeling, stimulating their migration through these specific
nanovesicles (i.e., exosomes).
MATERIALS AND METHODS
MATERIALS
Medium RPMI 1640, Medium 231, Smooth Muscle Growth
Supplement (SMGS), glutamine, antibiotics, HEPES, and phos-
phate buffered saline (PBS) were obtained from Life Technologies
Corporation (Mulgrave, Victoria, Australia). CD63 ELISA kits
were obtained from SBI (ExoELISA™, System Biosciences,
Mountain View, CA).
CELL CULTURE
All experimental procedures were conducted within an ISO17025
accredited (National Association of Testing Authorities, Australia)
research facility. All data were recorded within a 21 Code of
Federal Regulation (CFR) part 11 compliant electronic labora-
tory notebook (Irisnote, Redwood City, CA, USA). JEG-3 human
choriocarcinoma cell line was purchased from the European
Collection of Cell Cultures (Porton Down, Salisbury, UK). The
HTR-8/SVneo cell line was kindly donated by Dr. Charles H.
Graham (Queen’s University, Ontario, Canada). HTR-8/SVneo
was established by the transfection of trophoblast cells isolated
from first trimester villous explants, with a gene encoding simian
virus 40 large T antigen to immortalize them (Graham et al.,
1993). JEG-3 and HTR-8/SVneo cells were maintained in phe-
nol red-free RPMI 1640 medium supplemented with 10% heat-
inactivated fetal bovine serum, 1% non-essential amino acids,
1mM sodium pyruvate and 100U/mL penicillin, and 100mg/mL
streptomycin. Cultures were maintained at 37◦C and humidified
under an atmosphere of 5% CO2-balanced N2 to obtain 8% O2
(pO2 ∼54mmHg) in an automated PROOX 110-scaled hypoxia
chamber (BioSphericsacona, NY, USA). Cells were subcultured
with dissociation media, TrypLE™ Express (Life technologies,
USA) and cellular viability was determined by Trypan Blue exclu-
sion and Countess® Automated cell counter (Life Technologies,
USA).
Human Vascular Smooth Muscle cells (hVSMC) were pur-
chased from LONZA (Lonza Group Ltd.). VSMC were cultured
in 231 media (Life Technologies Corporation) supplemented
with SMGS, 100U/ml penicillin, and 100μg/ml streptomycin,
at 37◦C and humidified under an atmosphere of 5% CO2-
balanced N2 to obtain 8%O2 (pO2 ∼54mmHg) in an automated
PROOX 110-scaled hypoxia chamber (BioSpherics™, Lacona,
NY, USA).
The in vitro cell migration rates of JEG-3 and HTR-8/SVneo
we established using real-time cell imaging system (IncuCyte™
live-cell ESSEN BioScience Inc., Ann Arbor, MI, USA). Using
a scratch assay format, cell were imaged every 3 h to mon-
itor cell migration as previously described (Salomon et al.,
2013b).
EXOSOME ISOLATION
Exosomes were isolated from cell-free JEG-3 and HTR-8/SVneo-
conditionedmedia as previously described (Salomon et al., 2013a;
Kobayashi et al., 2014). In brief, cell-conditioned media was
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centrifuged at 300 × g for 15min, 2000 × g for 30min, and
12,000 × g for 45min to remove whole cells and debris. The
resultant supernatant were passed through a 0.22μm filter ster-
ilize Steritop™ (Millipore, Billerica, MA, USA) and then cen-
trifuged at 120,000 × g for 70min (Thermo Fisher Scientific
Ins., Asheville, NC, USA, Sorvall, SureSpin™ 630/36, fixed angle
rotor). The pellet was resuspended in PBS, washed and re-
centrifuged (120,000 × g, 75min). The pellet was resuspended
in PBS, layered on a cushion of 30% (w/v) sucrose and cen-
trifuged at 110,000 g for 75min. The fraction containing exo-
somes [∼3.5ml, 1.127 density using OPTi digital refractometer
(Bellingham+Stanley Inc., Lawrenceville, GA, USA)] was recov-
ered using a Pulse-Free Flow Peristaltic Pump with a flow rate
range of 1ml per min (GILSONMiniplus®model 3) and Fraction
Collector (GILSON FC 203Bmodel) and diluted in PBS, and then
ultracentrifuged at 110,000 × g of 70min. Recovered exosomes
were resuspended in 50μl PBS and their protein contents were
determined using the Bradford assay (Bio-Rad DC). Exosome
samples (5μl) were prepared by adding RIPA buffer (50mM Tris,
1% Triton × 100, 0.1% SDS, 0.5% DOC, 1mM EDTA, 150mM
NaCl, protease inhibitor) directly to exosomes suspended in PBS
and sonicated at 37◦C for 15 s three times to disrupt exosomes
and solubilise the proteins. Bovine serum albumin (BSA) diluted
in RIPA buffer and PBS mixture (1:1) were prepared as protein
standards (0, 200, 400, 600, 800, 1000, 1500μg/mL). Standards
and samples (exosomes) were transferred to 96-well plates and
procedures outlined by the manufacture were followed. In brief,
alkaline copper tartrate solution (Bio-Rab Laboratories, Hercules,
CA, USA) and dilute Folin Reagent (Bio-Rab Laboratories,) were
added to the samples and incubated for 15min. The absorbance
was read at 750 nm with Paradigm Detection Platform (Beckman
Coulter, USA).
NANOPARTICLE TRACKING ANALYSIS (NTA)
NTA measurements were performed using a NanoSight NS500
instrument (NanoSight NTA 2.3 Nanoparticle Tracking and
Analysis Release Version Build 0033) following the manufac-
turer’s instructions. The NanoSight NS500 instrument measured
the rate of Brownian motion of nanoparticles and consists in
a light scattering system that provides a reproducible platform
for specific and general nanoparticle characterization (NanoSight
Ltd., Amesbury, UK). Samples were processed in duplicate and
diluted with PBS over a range of concentration to obtain between
10 and 100 particles per image (optimal ∼50 particles × image)
before the analysis with the NTA system. The samples were mixed
before introducting into the chamber (temperature: 25◦C and
viscosity: 0.89 cP) and the camera level set to obtain an image
that had sufficient contrast to clearly identify particles while min-
imizing background noise with video recording (camera level:
10 and capture duration: 60 s). Afterwards, the capture videos
(2 videos per sample) were processed and analyzed. A combi-
nation of high shutter speed (450) and gain (250) followed by
manual focusing enables optimum visualization of the maxi-
mum number of vesicles. A minimum of 200 completed tracks
per video were collected in duplicate for each sample analyzed.
NTA post acquisition settings were optimized and kept constant
between samples (Frames Processed: 1496 of 1496, Frames per
FIGURE 1 | Extravillous Trophoblast invasion. JEG-3 and HTR-8/SVneo
cells were grown to confluence in complete media. A wound was made
using 96 well WoundMaker and cells were imaged with IncuCyte™ (Essen
BioSciences, USA) every 4 h for 40 h (see Materials and Methods). (A) Top:
Representative images of JEG-3 and HTR-8/SVneo cell migration at 16 h.
The gray region denotes the area of the initial wound covered by advancing
cells. Bottom: The time course of JEG-3 and HTR-8/SVneo migration. Insert:
half-maximal stimulatory time (ST50). (B) Area under curves analysis from
(A). Data represented as mean ± s.e.m. (n = 12). In (B) ∗∗∗p < 0.0001 vs.
HTR-8/SVneo.
Second: 30, camera shutter: 20ms; Calibration: 139 nm/pixel,
Blur: 3 × 3; Detection Threshold: 10; Min Track Length: Auto;
Min Expected Size: Auto), and each video was then analyzed to
give the mean, mode, and median particle size together with an
estimated number of particles. An Excel spreadsheet (Microsoft
Corp., Redmond, Washington) was also automatically generated,
recording the concentration at each particle size.
TRANSMISSION ELECTRON MICROSCOPY
Exosome pellets (as described above, 30μg protein) were fixed in
3% (w/v) glutaraldehyde and 2% paraformaldehyde in cacodylate
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FIGURE 2 | Characterization of exosome from EVT cells. Exosomes
were isolated from JEG-3 and HTR-8/SV cells by differential and
buoyant density centrifugation (see Materials and Methods).
(A–D) shown representative particles size distribution of exosomes
isolation steps from JEG-3 and HTR-8/SV cells. (A) After differential
centrifugation (i.e., 300 × g, 2000 × g, and 12,000 × g).
(B) Microsomal fraction prior sucrose density purification. (C) After
sucrose density purification (30% sucrose cushion). (D) Top:
representative Western blot for exosome markers: CD63. Bottom:
representative electron micrograph exosome fractions, Scale bar 200 nm.
buffer, pH 7.3. Exosome samples were then applied to a continu-
ous carbon grid and negatively stained with 2% uranyl acetate.
The samples were examined in an FEI Tecnai 12 transmission
electron microscope (FEI™, Hillsboro, OR, USA).
QUANTIFICATION OF CELL-DERIVED EXOSOME
The concentration of exosomes from EVT cells lines (JEG-
3 and HTR-8/SVneo) in maternal circulation was expressed
as total immunoreactive exosomal CD63 (ExoELISA™, System
Biosciences, Mountain View, CA). Briefly, 10μg of exosomal pro-
tein was immobilized in micro-titer plate wells and incubated
overnight (binding step). Plates were washed three times for 5min
using a wash buffer solution and then incubated with exosome
specific primary antibody (CD63) at room temperature (RT) for
1 h on a shaker. Plates were washed and incubated with secondary
antibody (1:5000) at RT 1 h on a shaker. Plates were washed
and incubated with Super-sensitive TMB ELISA substrate at RT
for 45min while shaking. The reaction was terminated using
Stop Buffer solution. Absorbance was measured at 450 nm. The
number of exosomes/ml, (ExoELISA™ kit) was obtained using
an exosomal CD63 standard curve calibrated against nanoparti-
cle tracking data (i.e., number of exosomes, NanoSight™). The
coefficients of intra- and inter-assay variations were less than 8%.
EFFECT OF EXOSOMES ON VASCULAR SMOOTH MUSCLE CELLS
(VSMC) MIGRATION
VSMC were cultured in 231 media supplemented with 0.2%
FBS-exosome free in 96-well culture plate (Corning Life Science,
Tewksbury, MA, USA) according to the manufacturer’s instruc-
tions for 18–24 h. Firstly, we analyzed the effect of cell prolifera-
tion on cell migration assay in our experimental conditions using
an anti-proliferative drug Mitomycin C (SIGMA-ALDRICH).
Cells were plated (1 × 105 cells per well) onto 24-well plate,
and after 24 h Mitomycin C (50 and 100 ng/ml) was added to
the cell for 48 h. Cell proliferation was quantified (time-curve)
by measuring the cell confluence using a real time imagining
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FIGURE 3 | Exosome releases from EVT cell lines. Exosomal protein and
number of exosomes were quantified cell conditioned media from JEG-3
and HTR-8/SVneo cells using a colorimetric assay and ELISA kit,
respectively. (A) exosomes concentration presented as μg exosomal
protein per 106 cells and (B) Number of exosomes particles. Data are
presented as scatter dot plot and values are mean ± s.e.m. In
(A,B) ∗∗∗p < 0.001 vs. HTR-8/SVneo.
system IncuCyte™. Simultaneously, VSMC migration assay in
the presence of Mitomycin C (50 and 100 ng/ml) for 48 h was
performed.
During experiments, VSMC cells were incubated in the pres-
ence (treatment: 100μg exosomal protein/ml) or absence (con-
trol) of exosomes for up to 48 h under 8% O2 (n = 12). The
concentration used in this study was based upon exosome dose-
response curves from our previously published studies (Salomon
et al., 2013a,b, 2014). Exosomes were subjected to heat inactiva-
tion (30min at 65◦C) or sonication for 30min (sonicator bath)
before the incubation on VSMC. Cell migration was assessed
using a scratch assay format. A scratch was made on confluent
monolayers using a 96-pin WoundMaker™ (BioScience Inc, Ann
Arbor, MI, USA). Wound images were automatically acquired
and registered by the IncuCyte™ software system. CellPlayer™
96-Well Invasion Assay software was use to fully automate data
collection. Data were processed and analyzed using IncuCyte™
96-Well Cell Invasion Software Application Module. Data are
presented as the Relative Wound Density (RWD, Eizen, v1.0 algo-
rithm). RWD is a representation of the spatial cell density in the
wound area relative to the spatial cell density outside of the wound
area at every time point (time-curve). Migration assays were per-
formed in the presence of Mitomycin C (100 ng/ml) to minimize
any confounding effects of cell proliferation. The rate of wound
closure was compared using the half-maximal stimulatory time
(ST50) and area under the time course curve (AUC).
EXOSOME INTERNALIZATION
For exosome uptake analysis, the exosomes pellet (before purifi-
cation using 30% sucrose cushion) isolated from JEG-3 and
HTR-8/SVneo cells was resuspended in PBS and stained with
PKH67 green fluorescent cell linker kit follow the manufacturer’s
instructions (Sigma-Aldrich). The staining reaction was stopped
after 5min with exosome-free FBS. Exosomes were then puri-
fied using 30% sucrose cushion as described above. Exosomes-
PKH67 (100μg/ml from JEG-3 and HTR-8/svneo cells) were
incubated on VSMC for 24 h and exosome uptake was quanti-
fied using IncuCyte™ (fluorescent mode). Simultaneously, VSMC
were grown in glass bottom chamber slides, and labeled exosomes
(100μg/ml) were added to subconfluent cells. After 24 h, VSMC
were washed and fixed using 2% paraformaldehyde for 5min
at RT. Cells were immediately analyzed using a Zeiss fluores-
cence microscope (Axio Imager M1, Zeiss EC Plan-NEOFLUAR
40×/0.75, the Carl Zeiss Group, Germany) with FITC and DAPI
absorbance setting.
PROTEOMIC ANALYSIS OF CYTOTROPHOBLAST DERIVED-EXOSOMES
BY MASS SPECTROMETRY (MS)
Isolated exosomes from JEG-3 and HTR-8/SVneo were solubi-
lized in 8M urea in 50mM ammonium bicarbonate, pH 8.5,
and reduced with DTT for 1 h. Proteins were then alkylated
in 10mM iodoacetic acid (IAA) for 1 h in the dark. The sam-
ple was diluted to 1:10 with 50mM ammonium bicarbonate
and digested with trypsin (20μg) at 37◦C for 18 h. The sam-
ples were desalted by solid phase extraction using a STAGE
tip protocol (Stop and go extraction tips for matrix-assisted
laser desorption/ionization, nano-electrospray, and LC/MS sam-
ple pre-treatment in proteomics). The eluted peptides were dried
by centrifugal evaporation to remove acetonitrile and redissolved
in Solvent A. The resulting peptide mixture was analyzed by liq-
uid chromatography (LC)/mass spectrometry (MS) LC-MS/MS
on a 5600 Triple TOFmass spectrometer (AB Sciex, Framingham,
USA) equipped with an Eksigent Nanoflow binary gradient HPLC
system and a nanospray III ion source. Solvent A was 0.1%
formic acid in water and solvent B was 0.1% formic acid in
acetonitrile. MS/MS spectra were collected using Information
Dependent Acquisition (IDA) using a survey scan (m/z 350–1500)
followed by 25 data-dependent product ion scans of the 25 most
intense precursor ions. All mass spectra were analyzed using the
Mascot and Protein Pilot search engines against the Swissprot-
database with the species set as human. Positive identifications
were ascribed where Mascot scores were greater than 30. False
discovery rate (FDR) was estimated using a reversed sequence
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FIGURE 4 | EVT-derived exosomes effects on hVSMC migration. hVSMC
were grown to confluence in 231 media and a wound was made using 96
well WoundMaker (see Materials and Methods). hVSMC Migration was
measured in absence or presence of 100 ug/ml of exosomes from JEG-3
and HTR-8/SVneo cells and mitomycin C (100 ng/ml) for 48 h. Exosome
particles were subjected to sonication (+sonication) or heat inactivation
(+heat) before exposure to hVSMC cells (A,B) hVSMC proliferation and
migration in the presence of Mitomycin C, respectively. (C) Time course of
wound closure for hVSMC expressed as relative wound density (%).
(D) Area under curves from data in (C). (E) Time-dependent uptake of
exosomes using a real time imaging system analysis. Top: images after
24 h; Bottom: Graphical representation of exosome uptake. (F) Fluorescent
microscopy analysis of exosome uptake (40X). Data represent an n = 12
well each point with 3 different cells culture. Values are mean ± SD. In
(D) ∗∗∗p < 0.001 vs. all condition except exo-HTR-8/SVneo + heat; and
†p < 0.05 vs. control. In (E) ∗p < 0.001 vs. corresponding values at 0 h;
‡p < 0.05 vs. corresponding values control at 4 h; †p < 0.05 vs.
corresponding values control at 8 and 4 h.
database. Finally, proteins identified were submitted to bioin-
formatic pathway analysis (Ingenuity Pathway Analysis [IPA];
Ingenuity Systems, Mountain View, CA; www.ingenuity.com).
STATISTICAL ANALYSIS
Data are represented as mean ± s.e.m. Comparisons between
two group means were performed by unpaired Student’s t-tests.
Multiple groups were compared using the analysis of variance
(ANOVA). Post-hoc analyses were used for pairwise comparisons
(Bonferroni correction test). Statistical significance was defined as
at least p < 0.05. Statistical analyses were preformed using com-
mercially available packages (Stata 11, StatCorp, College Station,
TX, USA and Prism 6, GraphPad Inc, La Jolla, CA 92037 USA).
RESULTS
CHARACTERIZATION OF EVT CELL LINES
Figure 1A presents photomicrographs of wound closure over 40 h
incubation for both cell lines and the percent change in relative
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wound density over time. The migration rate of HTR-8/SVneo
was significantly greater than that observed for JEG-3 cells.
Half-maximal stimulatory time (ST50) was 31.29 ± 0.14 h and
15.26 ± 0.15 h for JEG-3 and HTR-8SV/neo, respectively (p <
0.05, Figure 1A, bottom). Area under curves analysis showed that
the migration of HTR-8SV/neo was ∼2.0-fold greater than that
obtained for JEG-3 cells (Figure 1B).
CHARACTERIZATION OF EVT CELL LINE-DERIVED EXOSOMES
Defining vesicle size range is one of the standard metrics used
to confirm that the vesicle preparation in not contaminated with
non-exosome vesicles. After differential centrifugation (i.e., 300×
g, 2000 × g, and 12,000 × g), the supernatant was analyzed using
a nanoparticles tracking analysis (NTA). Particle size distribution
ranged from 30 to 500 nm, with an average of 180 ± 100 nm
(Figure 2A). Supernatant was filtered and ultracentrifuged to
obtain a particulate fraction (including exosomes particles) with
a particle size ranged of 30–200 nm (with a mean diameter of
119 ± 65 nm, Figure 2B). The exosomes were purified by ultra-
centrifugation over a sucrose cushion and analyzed using a NTA.
The exosome fractions displayed a particle size ranged from 30 to
150 nm in diameter (with mean of 79 ± 68 nm, Figure 2C). The
presence of exosomal marker CD63 in exosomes isolated from
both cell lines was confirmed by Western blot (Figure 2D, top).
Finally, exosomes isolated from JEG-3 and HTR-8/SVneo were
visualized by transmission electron microscopy (Figure 2D, bot-
tom). Exosomes were identified as small vesicles between 40 and
100 nm. No significant differences in NTA data, CD63 expression
and electron microscopy were identified between cell lines.
EXOSOME RELEASE FROM EVT CELL LINES
Exosomal protein release was expressed as total exosomal protein
(i.e., particulate material with a buoyant density of 1.127 g/ml)
per million cells/24 h. JEG-3 cells released 46 ± 16 ng exoso-
mal protein per million cells per 24 h (n = 4; i.e., 4 different
isolations from ∼ 200 × 106 cells each) whereas HTR-8/SVneo
cells released 120 ± 35 ng exosomal protein per million cells
per 24 h (n = 4, Figure 3A). HTR-8/SVneo cells released signif-
icantly more exosomes (∼2.6-folds) in 24 h compared to JEG-3
cells (p < 0.0001). These results were confirmed by quantify-
ing immunoreactive exosomal CD63. The number of exosomes
(NEP) released from HTR-8/SVneo cells (6.39 × 108 ± 2.5 ×
108/24 h) was ∼2.3-fold greater (p < 0.0001) than that observed
for JEG-3 cells (2.86 × 108 ± 0.78 × 108/24 h, Figure 3B).
EFFECT OF EVT-DERIVED EXOSOMES ON CELL MIGRATION
A VSMC was used to establish the effects of EVT-derived exo-
somes on cell migration. An anti-proliferative drug Mitomycin
C (50 and 100 ng/ml) reduces significantly (p < 0.01) VSMC
proliferation (Figure 4A). A dose of 100 ng/ml decreased VSMC
migration compared to 50 ng/ml of Mitomycin C and control
(Figure 4B). The effects of exosomes (100μg protein/ml) isolated
from JEG-3 and HTR-8/SVneo cultured under 8% O2 on VSMC
migration under 8%O2 are presented in Figures 4C,D. All exper-
iments were done in the presence of Mitomycin C (100 ng/ml).
The rate of wound closure was significantly increased in the
presence of HTR-8/SVneo-derived exosome compared to control
(-exosomes) as measured by ST50 (15.57 ± 0.32 vs. 25.09 ±
0.58, p < 0.01) (Table 1). Area under curves analysis showed that
HTR-8/SVneo-derived exosome increased ∼35 ± 0.2% VSMC
migration compared to control. Similarly, exosomes from JEG-3
cells increased VSMC migration ∼12 ± 0.1% compared to val-
ues in the absence of exosomes (control), however, the effect was
smaller compared to exosomes from HTR-8/SVneo. Exosomes
were exposed to heat inactivation before incubation on VSMC;
however, heat inactivation did not affect the effect of exosomes
onVSMCmigration. In contrast, sonication completely abolished
the HTR-8/SVneo and JEG-3-derived exosomes effect on VSMC
migration.
The internalization of exosomes labeled with PKH67 (green)
in VSMC was quantified and visualized using The IncuCyte and
a fluorescence microscope, respectively (Figures 4E,F). Exosome
uptake by VSMC was observed in a time-dependent manner with
the maximum at 24 h (Figure 4E, top panel a and c). Sonication
abolished the uptake of fluorescent exosomes (Figure 4E, top
panel b and d) compared to exosomes without sonication.
Exosome uptake is presented as fluorescent per cell confluence
normalized to maximum uptake of 100%. Heat inactivation did
not affect the exosomes uptake by VSMC (Figure 4, lower panel).
Finally, fluorescence microscope analysis showed an intracellular
fluorescent in VSMC cells exposed to intact vesicles from JEG-3
and HTR-8/SVneo (Figure 4F).
PROTEOMIC ANALYSIS OF EVT-DERIVED EXOSOME
Mass spectrometry analysis identified over 140 exosomal pro-
teins, including cell-line specific exosomal proteins (Table 2 and
Figure 5A). Exosomal proteins isolated from JEG-3 and HTR-
8/SVneo cells were associated with cellular movement and mor-
phology, immune cell trafficking and cellular assembly and orga-
nization in accordance with Ingenuity Pathway Analysis (IPA)
analysis. The canonical pathways associated with our exosomal
proteins isolated from JEG-3 and HTR-8/SVneo cells and defined
by IPA Core comparison analysis showed that the score (−log [p-
value]) for proteins associated with cell movement and migration
was significantly higher (∼1.2-fold, p < 0.05) in HTR-8/SVneo-
derived exosomes to compare to exosomes from JEG-3 cells
(Figure 5B).
Table 1 | Kinetic characteristic of exosome effects on hVSMC
migration.
Condition ST50 (hours)
Control 25.09± 0.58
+exo-JEG-3 21.83± 0.49‡
+exo-HTR-8/SVneo 15.57± 0.32*
+exo-JEG-3 + sonication 25.06± 0.46
+exo-HTR-8/SVneo + sonication 23.27± 0.48
+exo-JEG-3 + heat 24.14± 0.35
+exo-HTR-8/SVneo + heat 19.43± 0.34†
The effect of exosomes isolated from JEG-3 and HTR-8/SVneo-conditioned
media on hVSMC in vitro migration. Data are expressed as half-maximal
Stimulatory Time (ST50 in hours) and represent the mean ± SD. *p < 0.05 vs.
control; †p < 0.005 vs. control and +exo-HTR-8/SVneo. ‡p < 0.005 vs. control.
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Table 2 | List of proteins identified in exosomes isolated from JEG-3 and HTR-8/SVneo cells.
Symbol Entrez gene name UniProt/Swiss-Prot
accession
Location Type(s)
COMMON PROTEINS IN EXOSOMES FROM JEG-3 and HTR-8/Svneo CELLS
A2M Alpha-2-macroglobulin A2MG_HUMAN Extracellular space Transporter
ACTB Actin, beta ACTB_HUMAN Cytoplasm Other
AHSG Alpha-2-HS-glycoprotein FETUA_HUMAN Extracellular space Other
ALB Albumin ALBU_HUMAN Extracellular space Transporter
APOE Apolipoprotein E APOE_HUMAN Extracellular space Transporter
APOM ApolipoproteinM APOM_HUMAN Plasma membrane Transporter
C3 Complement component 3 CO3_HUMAN Extracellular space Peptidase
EEF2 Eukaryotic translation elongation factor 2 EF2_HUMAN Cytoplasm Translation regulator
ENO1 Enolase 1, (alpha) ENOA_HUMAN Cytoplasm Enzyme
F5 Coagulation factor V (proaccelerin, labile factor) FA5_HUMAN Plasma membrane Enzyme
FGB Fibrinogen beta chain FIBB_HUMAN Extracellular space Other
FLNA Filamin A, alpha FLNA_HUMAN Cytoplasm Other
FN1 Fibronectin 1 FINC_HUMAN Extracellular space Enzyme
HSP90AA1 Heat shock protein 90 kDa alpha (cytosolic), class A
member 1
HS90A_HUMAN Cytoplasm Enzyme
HSPA8 Heat shock 70 kDa protein 8 HSP7C_HUMAN Cytoplasm Enzyme
KRT1 Keratin 1 K2C1_HUMAN Cytoplasm Other
KRT10 Keratin 10 K1C10_HUMAN Cytoplasm Other
LDHB Lactate dehydrogenase B LDHB_HUMAN Cytoplasm Enzyme
MSN Moesin MOES_HUMAN Plasma membrane Other
PGK1 Phosphoglycerate kinase 1 PGK1_HUMAN Cytoplasm Kinase
PKM Pyruvate kinase, muscle KPYM_HUMAN Cytoplasm Kinase
PZP Pregnancy-zone protein PZP_HUMAN Extracellular space Other
THBS1 Thrombospondin 1 TSP1_HUMAN Extracellular space Other
VEPH1 Ventricular zone expressed PH domain-containing 1 MELT_HUMAN Nucleus Other
YWHAB Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, beta
1433B_HUMAN Cytoplasm Transcription regulator
YWHAE Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, epsilon
1433E_HUMAN Cytoplasm Other
EXOSOMES FROM JEG-3 CELLS
ACTN1 Actinin, alpha 1 ACTN1_HUMAN Cytoplasm Other
ADAMTS13 ADAM metallopeptidase with thrombospondin type 1
motif, 13
ATS13_HUMAN Extracellular space Peptidase
AFP Alpha-fetoprotein FETA_HUMAN Extracellular space Transporter
AHCY Adenosylhomocysteinase SAHH_HUMAN Cytoplasm Enzyme
AMY2A Amylase, alpha 2A (pancreatic) AMYP_HUMAN Extracellular space Enzyme
APOA1 Apolipoprotein A-I APOA1_HUMAN Extracellular space Transporter
ARGLU1 Arginine and glutamate rich 1 ARGL1_HUMAN Other Other
ATP10A ATPase, class V, type 10A AT10A_HUMAN Plasma membrane Transporter
C5 Complement component 5 CO5_HUMAN Extracellular space Cytokine
C7 Complement component 7 CO7_HUMAN Extracellular space Other
C4A/C4B Complement component 4B (Chido blood group) CO4A_HUMAN Extracellular space Other
C8B Complement component 8, beta polypeptide CO8B_HUMAN Extracellular space Other
CLEC11A C-type lectin domain family 11, member A CLC11_HUMAN Extracellular space Growth factor
COL6A1 Collagen, type VI, alpha 1 CO6A1_HUMAN Extracellular space Other
COLGALT1 Collagen beta(1-O)galactosyltransferase 1 GT251_HUMAN Cytoplasm Other
COMP Cartilage oligomeric matrix protein COMP_HUMAN Extracellular space Other
CPN1 Carboxypeptidase N, polypeptide 1 CBPN_HUMAN Extracellular space Peptidase
DGKQ Diacylglycerol kinase, theta 110 kDa DGKQ_HUMAN Cytoplasm Kinase
EEF1A2 Eukaryotic translation elongation factor 1 alpha 2 EF1A2_HUMAN Cytoplasm Translation regulator
F2 Coagulation factor II (thrombin) THRB_HUMAN Extracellular space Peptidase
(Continued)
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Table 2 | Continued
Symbol Entrez gene name UniProt/Swiss-Prot
accession
Location Type(s)
F10 Coagulation factor X FA10_HUMAN Extracellular space Peptidase
F13A1 Coagulation factor XIII, A1 polypeptide F13A_HUMAN Extracellular space Enzyme
FBLN1 Fibulin 1 FBLN1_HUMAN Extracellular space Other
FGG Fibrinogen gamma chain FIBG_HUMAN Extracellular space Other
GC Group-specific component (vitamin D binding protein) VTDB_HUMAN Extracellular space Transporter
GSN Gelsolin GELS_HUMAN Extracellular space Other
H2AFV H2A histone family, member V H2AV_HUMAN Nucleus Other
HBB Hemoglobin, beta HBB_HUMAN Cytoplasm Transporter
HIST1H1T Histone cluster 1, H1t H1T_HUMAN Nucleus Other
HIST1H2BB Histone cluster 1, H2bb H2B1B_HUMAN Nucleus Other
HSPA1L Heat shock 70kDa protein 1-like HS71L_HUMAN Other Other
IGLL1/IGLL5 Immunoglobulin lambda-like polypeptide 1 IGLL5_HUMAN Plasma membrane Other
ITIH1 Inter-alpha-trypsin inhibitor heavy chain 1 ITIH1_HUMAN Extracellular space Other
ITIH2 Inter-alpha-trypsin inhibitor heavy chain 2 ITIH2_HUMAN Extracellular space Other
ITIH3 Inter-alpha-trypsin inhibitor heavy chain 3 ITIH3_HUMAN Extracellular space Other
LINC00083 Long intergenic non-protein coding RNA 83 YA021_HUMAN Other Other
LRP1 Low density lipoprotein receptor-related protein 1 LRP1_HUMAN Plasma membrane Transmembrane
receptor
LUM Lumican LUM_HUMAN Extracellular space Other
MYH9 Myosin, heavy chain 9, non-muscle MYH9_HUMAN Cytoplasm Transporter
MYL6 Myosin, light chain 6, alkali, smooth muscle and non-muscle MYL6_HUMAN Cytoplasm Other
NHSL2 NHS-like 2 NHSL2_HUMAN Other Other
OR2W3 Olfactory receptor, family 2, subfamily W, member 3 OR2W3_HUMAN Plasma membrane G-protein coupled
receptor
PIF1 PIF1 5′-to-3′ DNA helicase PIF1_HUMAN Nucleus Enzyme
PITRM1 Pitrilysin metallopeptidase 1 PREP_HUMAN Cytoplasm Peptidase
PLG Plasminogen PLMN_HUMAN Extracellular space Peptidase
PPP6R3 Protein phosphatase 6, regulatory subunit 3 PP6R3_HUMAN Cytoplasm Other
RAN RAN, member RAS oncogene family RAN_HUMAN Nucleus Enzyme
RDH13 Retinol dehydrogenase 13 (all-trans/9-cis) RDH13_HUMAN Cytoplasm Enzyme
SERPINA7 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
antitrypsin), member 7
THBG_HUMAN Extracellular space Transporter
SERPINF1 Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin,
pigment epithelium derived factor), member 1
PEDF_HUMAN Extracellular space Other
SERPINF2 Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin,
pigment epithelium derived factor), member 2
A2AP_HUMAN Extracellular space Other
THBS4 Thrombospondin 4 TSP4_HUMAN Extracellular space Other
TLN1 Talin 1 TLN1_HUMAN Plasma membrane Other
TUBA1B Tubulin, alpha 1b TBA1B_HUMAN Cytoplasm Other
TUBA4A Tubulin, alpha 4a TBA4A_HUMAN Cytoplasm Other
VTN Vitronectin VTNC_HUMAN Extracellular space Other
YWHAZ Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, zeta
1433Z_HUMAN Cytoplasm Enzyme
ZNF480 Zinc finger protein 480 ZN480_HUMAN Nucleus Other
EXOSOMES FROM HTR-8/SVneo CELLS
AASDH Aminoadipate-semialdehyde dehydrogenase ACSF4_HUMAN Other Enzyme
ACTN4 Actinin, alpha 4 ACTN4_HUMAN Cytoplasm Other
ALDOA Aldolase A, fructose-bisphosphate ALDOA_HUMAN Cytoplasm Enzyme
ANXA2 Annexin A2 ANXA2_HUMAN Plasma membrane Other
ANXA5 Annexin A5 ANXA5_HUMAN Plasma membrane Other
ANXA6 Annexin A6 ANXA6_HUMAN Plasma membrane Other
APOB Apolipoprotein B APOB_HUMAN Extracellular space Transporter
(Continued)
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Table 2 | Continued
Symbol Entrez gene name UniProt/Swiss-Prot
accession
Location Type(s)
ARAP2 ArfGAP with RhoGAP domain, ankyrin repeat and PH
domain 2
ARAP2_HUMAN Cytoplasm Other
ART4 ADP-ribosyltransferase 4 (Dombrock blood group) NAR4_HUMAN Nucleus Enzyme
ATP1A1 ATPase, Na+/K+ transporting, alpha 1 polypeptide AT1A1_HUMAN Plasma membrane Transporter
B2M Beta-2-microglobulin B2MG_HUMAN Plasma membrane Transmembrane
receptor
BASP1 Brain abundant, membrane attached signal protein 1 BASP1_HUMAN Nucleus Transcription regulator
BMS1 BMS1 ribosome biogenesis factor BMS1_HUMAN Nucleus Other
C9 Complement component 9 CO9_HUMAN Extracellular space Other
C7orf61 Chromosome 7 open reading frame 61 CG061_HUMAN Other Other
CD59 CD59 molecule, complement regulatory protein CD59_HUMAN Plasma membrane Other
CHM Choroideremia (Rab escort protein 1) RAE1_HUMAN Cytoplasm Enzyme
CLTC Clathrin, heavy chain (Hc) CLH1_HUMAN Plasma membrane Other
COL12A1 Collagen, type XII, alpha 1 COCA1_HUMAN Extracellular space Other
FLNB Filamin B, beta FLNB_HUMAN Cytoplasm Other
FSCN1 Fascin homolog 1, actin-bundling protein
(Strongylocentrotus purpuratus)
FSCN1_HUMAN Cytoplasm Other
GAPDH Glyceraldehyde-3-phosphate dehydrogenase G3P_HUMAN Cytoplasm Enzyme
GLP2R Glucagon-like peptide 2 receptor GLP2R_HUMAN Plasma membrane G-protein coupled
receptor
GNAI2 Guanine nucleotide binding protein (G protein), alpha
inhibiting activity polypeptide 2
GNAI2_HUMAN Plasma membrane Enzyme
GNB1 Guanine nucleotide binding protein (G protein), beta
polypeptide 1
GBB1_HUMAN Plasma membrane Enzyme
GNG12 Guanine nucleotide binding protein (G protein), gamma 12 GBG12_HUMAN Plasma membrane Enzyme
HBD Hemoglobin, delta HBD_HUMAN Other Transporter
HIST1H1D Histone cluster 1, H1d H13_HUMAN Nucleus Other
HIST1H2BD Histone cluster 1, H2bd H2B1D_HUMAN Nucleus Other
HMCN1 Hemicentin 1 HMCN1_HUMAN Extracellular space Other
HSP90AB1 Heat shock protein 90 kDa alpha (cytosolic), class B
member 1
HS90B_HUMAN Cytoplasm Enzyme
HSPB1 Heat shock 27 kDa protein 1 HSPB1_HUMAN Cytoplasm Other
HSPE1 Heat shock 10 kDa protein 1 CH10_HUMAN Cytoplasm Enzyme
ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3
receptor)
ITA3_HUMAN Plasma membrane Other
ITGB1 Integrin, beta 1 (fibronectin receptor, beta polypeptide,
antigen CD29 includes MDF2, MSK12)
ITB1_HUMAN Plasma membrane Transmembrane
receptor
KRT9 Keratin 9 K1C9_HUMAN Cytoplasm Other
LGALS1 Lectin, galactoside-binding, soluble, 1 LEG1_HUMAN Extracellular space Other
MFGE8 Milk fat globule-EGF factor 8 protein MFGM_HUMAN Extracellular space Other
MIF Macrophage migration inhibitory factor
(glycosylation-inhibiting factor)
MIF_HUMAN Extracellular space Cytokine
NCL Nucleolin NUCL_HUMAN Nucleus Other
NME2 NME/NM23 nucleoside diphosphate kinase 2 NDKB_HUMAN Nucleus Kinase
NRG1 Neuregulin 1 NRG1_HUMAN Other Growth factor
PARK7 Parkinson protein 7 PARK7_HUMAN Nucleus Enzyme
PGAM1 Phosphoglycerate mutase 1 (brain) PGAM1_HUMAN Cytoplasm Phosphatase
PRDX1 Peroxiredoxin 1 PRDX1_HUMAN Cytoplasm Enzyme
PTGFRN Prostaglandin F2 receptor inhibitor FPRP_HUMAN Plasma membrane Other
RUVBL2 RuvB-like AAA ATPase 2 RUVB2_HUMAN Nucleus transcription regulator
S100A11 S100 calcium binding protein A11 S10AB_HUMAN Cytoplasm Other
SERPINA1 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
antitrypsin), member 1
A1AT_HUMAN Extracellular space Other
(Continued)
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Table 2 | Continued
Symbol Entrez gene name UniProt/Swiss-Prot
accession
Location Type(s)
SLC16A3 Solute carrier family 16 (monocarboxylate transporter),
member 3
MOT4_HUMAN Plasma membrane Transporter
SLC2A1 Solute carrier family 2 (facilitated glucose transporter),
member 1
GTR1_HUMAN Plasma membrane Transporter
STARD13 StAR-related lipid transfer (START) domain containing 13 STA13_HUMAN Cytoplasm Other
SYN1 Synapsin I SYN1_HUMAN Plasma membrane Transporter
TMEM262 Transmembrane protein 262 YK025_HUMAN Other Other
TPI1 Triosephosphate isomerase 1 TPIS_HUMAN Cytoplasm Enzyme
TRRAP Transformation/transcription domain-associated protein TRRAP_HUMAN Nucleus Transcription regulator
TUBBP5 Tubulin, beta pseudogene 5 YI016_HUMAN Other Other
UBAC2 UBA domain containing 2 UBAC2_HUMAN Cytoplasm Enzyme
VIM Vimentin VIME_HUMAN Cytoplasm Other
All mass spectra were analyzed using the Mascot and Protein Pilot search engines against the Swissprot-swissprot database with the species set as human (score
over 30). Exosomal proteins identified by mass-spectrometry were analyzed with the Ingenuity Pathway Analysis (Ingenuity Systems, www .ingenuity .com). False
discovery rate (FDR) was estimated using a reversed sequence database. List of total exosomal protein from cytotrophoblast cells exposed to different oxygen level
are presented as Protein ID, Symbol, Entrez Gene Name, Location, and type.
FIGURE 5 | Analysis of EVT cell-derived exosomes proteins. (A) The
Venn diagram represents the distribution of common and unique proteins
identified by nanospray LC-MS/MS (ABSciex 5600) in exosomes released
from JEG-3 and HTR-8/SVneo cells. (B) Comparison of biological function
(cell movement and migration) identified by IPA core analysis. In (B) values
are mean ± s.e.m. In (B) ∗p < 0.05 vs. HTR-8/SVneo cells.
DISCUSSION
A tenet of contemporary obstetrics is that events that compromise
placentation and the development of the materno-fetal exchange
increase the risk of complications of pregnancy and contribute to
poor pregnancy outcome. In particular, conditions that affect the
differentiation and invasion of placental cells compromise placen-
tal perfusion and function (Jauniaux et al., 2006, 2010; Burton
et al., 2009) and the subsequent growth and development of the
fetus (Khong et al., 1987). EVT migrate into maternal decidua
and myometrium and interact with VSMC in uterine spiral arter-
ies. Conversion of these arteries is associated with the loss of
VSMC from the vessel wall by migration out of the vessel. In this
study we established that: (1) exosome isolated from EVT-like
cell lines (JEG-3 and HTR-8/SVneo) with different cellular ori-
gins (choriocarcinoma and EVT) exhibit differences in their rate
of release, protein content and bioactivity; and (2) both exosomes
from JEG-3 and HTR-8/SVneo cells increase VSMC migration.
However, the effect of exosomes from HTR-8/SVneo was signifi-
cantly higher. Exosomes released from first trimester trophoblast
cells (EVT), therefore, may regulate processes that play a key role
in placentation and remodeling of the uterine spiral arteries.
The interactions between EVT and VSMC are not fully under-
stood, in part due to difficulties of accessing first trimester
samples and the lack of suitable animal models (Carter, 2007;
Ackerman et al., 2013). We obtained nanovesicles with high
purity. The data presented establish that the final preparation
used display a size distribution and buoyant consistent with exo-
somes and the lack of significant contamination by microsomes.
In this study, we quantified the release of exosomes from JEG-3
and HTR-8/SVneo cells (as indicated by immunoreactive exo-
somal CD63). The data obtained establish that exosome release
is cell type specific and correlated with cell migration capacity.
Consistent with these data, a correlation between exosome release
and cell invasiveness has been described previously in ovarian
cancer cells (Kobayashi et al., 2014).
The initial stages of uterine SpA remodeling involves a loss of
the VSMC component by apoptosis, migration or a combination
of both processes. In this study, we identify a novel exosomal sig-
naling pathway by which EVT (HTR-8/SVneo cells) promote the
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migration of VSMC. Consistent with these data, Bulmer et al.
(2012) observed that VSMC migration plays a major role in
remodeling of the artery by migration into the decidua and ves-
sel lumen and this phenomenon is enhanced in the presence of
EVT cells (Bulmer et al., 2012). Based upon the available data,
we propose that perivascular EVT release exosomes that interac-
tion with VSMC and promote their migration out of SpAs and
alter the vasoreactive of these vessels. This effect of exosomes
on VSMC migration was cell-type specific (i.e., only exosomes
from HTR-8/SVneo cells promote cell migration) and may reflect
the different cellular origin of the two cell lines compared in
this study. HTR-8/SVneo cells are derived by transfection of first
trimester trophoblast cells (Graham et al., 1993). JEG-3 cells are
derived from a choriocarcinoma (Kohler and Bridson, 1971).
Difference in the molecular cargo carried by exosomes released
fromHTR-8/SVneo and JEG-3 cell may account for their different
effects on target cell migration. Consistent with this suggestion,
proteins involved in cell migration were differentially represented
in exosomes isolated from the two-cell lines.
The exosomal content is highly dependent on the cell ori-
gin and on pre-conditioning of the cell. Exosomes function as
a carrier of specific molecules such as, proteins, lipids, mRNA,
and miRNA and can interact with neighboring cells or travel
long distances in the bloodstream to reprogram the phenotype
and regulate their function (Denzer et al., 2000). In this study,
we identified unique proteins (58 and 59 proteins in exosome
from JEG-3 and HTR-8/SVneo cells) and common proteins (26)
between these EVT cell lines. Ingenuity Pathway Analysis (IPA)
of exosomal proteins identified cell-dependent changes in cell
movement and migration signaling pathways. Exosomes have
been reported to express a diverse range of cell surface receptors,
proteins (including, heat shock proteins, cytoskeletal proteins,
adhesion molecules, membrane transport, and fusion proteins),
mRNA and miRNA with the potential to affect the acute and
long-term function of the cells with which they interact (Ambros,
2004). Recent data demonstrate that trophoblast-derived exo-
somes induce proinflammatory cytokines such IL-1 β in human
macrophages cells (Atay et al., 2011). Furthermore, in vitro expo-
sure of PBMC and dendritic cells to exosomal proteins induce
differentiation of stem cells; suppression of activation of natural
killer cells and macrophages; and stimulation of cell migration
(Mincheva-Nilsson et al., 2006; Knight, 2008; Soo et al., 2012).
Interestingly, protein analysis revealed that exosome release from
cytrophoblast cells increases with low oxygen tension and their
exosome promotes cell migration in extravillous cytotrophoblast
(HTR-8/SVneo) (Salomon et al., 2013b).
The observed effects of HTR-8/SVneo-derived exosomes on
VSCM migration were also dependent upon exosome structural
integrity. Disruption of exosomes by sonication (Delorme-Axford
et al., 2013) completely abolished their effect on VSMC migra-
tion.While the precise mechanisms by which sonication abolishes
the effects of exosomes remains to be established, preventing
exosomal fusion with VSMC cell membrane and the intracel-
lular delivery of signaling molecules and/or the loss of capacity
to appropriately present exosomal surface moieties to target cell
receptors represent possible pathways and warrant further investi-
gation. We establish in this study that exosome integrity is critical
to mediating their effects on VSMC migration. It is not possi-
ble from the data obtained in this study to differentiate between
sonication–induced disruption of exosome: uptake; fusion; acti-
vation of VSMC cell surface receptors, or a combination of these
(and other) mechanisms. The elucidation of contribution of these
mechanisms will require additional extensive studies to establish.
In conclusion, using in vitro EVT-like cell lines, we have
demonstrated difference in release, composition and bioactivity
between exosomes from JEG-3 andHTR-8/SVneo cells. Exosomes
released from EVT may play a role in remodeling SpA by pro-
motingmigration of VSMC. Exosomal-induced VSCMmigration
is associated with increased representation of proteins involved
in cell migration processes within their molecular cargo and
dependent upon exosomal structural integrity. The identification
of this EVT-VSMC exosomal communication pathway not only
affords opportunity for developing biomarkers of placentation
but also the assessment of exosome targeted therapeutic inner-
vation strategies.
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